Clinical Trial Search

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation

Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions

Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L

Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio

Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05

Primary: Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests…

Primary: 6 Minute Walk Distance — 458.2; 466.1 meters

Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85

Primary: COPD Diagnosis — 39 participants

Primary: Pre-dose FEV1 — 1.079; 1.009 Ratio — p=<.0001

Primary: Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US — 65.6; 64.4 Years

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Effect of Intervention on Quality of Patient Clinician Communication About End-of-Life Care(QOC) Scale — 23.3; 19.2; 34.0; 25.5 units on a scale — p=0.03

Primary: Participation in Tobacco Cessation Treatment — 9; 29 Participants

Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941

Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale

Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84

Primary: Device Tidal Volume — 180 mL

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months — -0.004; -0.023; -0.018; -0.035 Liters

Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…

Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042

Primary: Patients Who Experienced at Least One Adverse Events(s) — 9; 10; 6 Participants